Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) rose by more than 4% this month, and its stock price increased by more than 30%. The company is expected to benefit from fair value earnings at monkey prices

The Zhitong Finance App learned that Zhaoyan New Pharmaceutical (06127) has risen by more than 4%, and its stock price has already risen by more than 30% this month. As of press release, it rose 4.04% to HK$22.14, with a turnover of HK$208 million.

According to the news, according to the Beijing Commercial Daily, the price of experimental monkeys showed an accelerated upward trend on December 9, about 140,000 yuan/dog. Fangzheng Securities pointed out that experimental monkeys are a rigid resource for pre-clinical safety assessments, and demand is increasing as pre-clinical CRO orders pick up steadily; moreover, it is difficult to expand production in the short term on the supply side. Some monkey farms indicated that production capacity has been scheduled until the first quarter of 2026. It is expected that supply and demand will remain tight, and short-term prices are expected to rise further.

According to estimates by Fangzheng Securities, taking Zhaoyan New Drug as an example, assuming that the fair value of 84,900 monkeys is included according to the average price of experimental monkeys in 2024 and the 2025Q4 price increase to 140,000/dog, assuming that the release rate of monkeys in the 2024 Q4 is 17%. According to estimates of the known 23,200 monkeys, Mao estimates (not considering the effects of newly added monkeys and young & elderly monkeys) will add about 220 million fair value in 2025.